Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


23.09.2024

1 BMC Urol
1 Cancer Imaging
2 Clin Cancer Res
3 Eur Radiol
11 Eur Urol
2 Int J Oncol
2 Int J Radiat Oncol Biol Phys
2 J Clin Oncol
1 J Nucl Med
2 J Urol
1 Lancet Oncol
1 Oncogene
1 Oncol Rep
4 Prostate
2 Radiol Imaging Cancer
1 Urology


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BMC Urol

  1. LI Z, Tan J, Wang Y, Ai C, et al
    Benign glomus tumor of prostate: a case report.
    BMC Urol. 2024;24:204.
    PubMed         Abstract available


    Cancer Imaging

  2. VENTURA D, Rassek P, Schindler P, Akkurt BH, et al
    Early treatment response assessment with [(177)Lu]PSMA whole-body-scintigraphy compared to interim PSMA-PET.
    Cancer Imaging. 2024;24:126.
    PubMed         Abstract available


    Clin Cancer Res

  3. DALLOS MC, Obradovic AZ, McCann P, Chowdhury N, et al
    Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer.
    Clin Cancer Res. 2024 Sep 13. doi: 10.1158/1078-0432.CCR-24-0060.
    PubMed         Abstract available

  4. JENSEN JL, Bobek O, Chan ICC, Miller BC, et al
    Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201).
    Clin Cancer Res. 2024 Sep 17:OF1-OF10. doi: 10.1158/1078-0432.CCR-24-0803.
    PubMed         Abstract available


    Eur Radiol

  5. BOSCHHEIDGEN M, Schimmoller L, Radtke JP, Kastl R, et al
    MRI characteristics predict risk of pathological upgrade in patients with ISUP grade group 1 prostate cancer.
    Eur Radiol. 2024 Sep 13. doi: 10.1007/s00330-024-11062.
    PubMed         Abstract available

  6. HAMM CA, Baumgartner GL, Padhani AR, Frobose KP, et al
    Reduction of false positives using zone-specific prostate-specific antigen density for prostate MRI-based biopsy decision strategies.
    Eur Radiol. 2024;34:6229-6240.
    PubMed         Abstract available

  7. MARVASO G, Isaksson LJ, Zaffaroni M, Vincini MG, et al
    Can we predict pathology without surgery? Weighing the added value of multiparametric MRI and whole prostate radiomics in integrative machine learning models.
    Eur Radiol. 2024;34:6241-6253.
    PubMed         Abstract available


    Eur Urol

  8. CHEN DC, Thomson A, Mazzone E, Perera ML, et al
    Re: Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer.
    Eur Urol. 2024 Sep 20:S0302-2838(24)02513-2. doi: 10.1016/j.eururo.2024.
    PubMed        

  9. FRANCINI E, Agarwal N, Castro E, Cheng HH, et al
    Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review.
    Eur Urol. 2024 Sep 20:S0302-2838(24)02599-5. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available

  10. BOEVE LMS, Hulshof MCCM, Verhagen PCMS, Twisk JWR, et al
    Prostate Cancer-related Events in Patients with Synchronous Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate; Data from the HORRAD Trial.
    Eur Urol. 2024 Sep 19:S0302-2838(24)02593-4. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available

  11. AZIZ MK, Molony D, Monlezun D, Holder T, et al
    Prostate Cancer Therapy Cardiotoxicity Map (PROXMAP) for Advanced Disease States: A Systematic Review and Network Meta-analysis with Bayesian Modeling of Treatment Histories.
    Eur Urol. 2024 Sep 18:S0302-2838(24)02569-7. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available

  12. WEINER AB, Agrawal R, Wang NK, Sonni I, et al
    Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naive Prostate Cancer.
    Eur Urol. 2024 Sep 17:S0302-2838(24)02597-1. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available

  13. BJERNER J, Bratt O, Aas K, Albertsen PC, et al
    Reply to Rongkang Li, Lei Peng, Shaohua Zhang, and Song Wu's Letter to the Editor re: Johan Bjerner, Ola Bratt, Kirsti Aas, et al. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the No
    Eur Urol. 2024 Sep 17:S0302-2838(24)02575-2. doi: 10.1016/j.eururo.2024.
    PubMed        

  14. BRATT O
    Prostate Cancer Screening: Setting the Controls on the Mixing Board.
    Eur Urol. 2024 Sep 17:S0302-2838(24)02598-3. doi: 10.1016/j.eururo.2024.
    PubMed        

  15. NIAZI T, Nabid A, Malagon T, Tisseverasinghe S, et al
    Hypofractionated Dose Escalation Radiotherapy for High-risk Prostate Cancer: The Survival Analysis of the Prostate Cancer Study 5, a Groupe de Radio-oncologie Genito-urinaire du Quebec-led Phase 3 Trial.
    Eur Urol. 2024 Sep 12:S0302-2838(24)02574-0. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available

  16. ROUVIERE O, van Leenders GJLH, Eberli D
    Systematic Prostate Biopsy Versus Perilesional Sampling: If It Isn't Broke, Why Fix It?
    Eur Urol. 2024;86:295-296.
    PubMed         Abstract available

  17. BROWN JR, Sonpavde GP, Calaway A, Barata PC, et al
    Circulating Tumor DNA To Assess Minimal Residual Disease: Versatile, but How Valuable?
    Eur Urol. 2024;86:312-314.
    PubMed        

  18. CIMADAMORE A, Giannarini G, Crestani A, Lopez-Beltran A, et al
    How To Report the Minor Component of a High-grade Pattern in Radical Prostatectomy Specimens: Time To Abandon the "Tertiary" Terminology?
    Eur Urol. 2024;86:291-294.
    PubMed         Abstract available


    Int J Oncol

  19. XU Y, Zhang G, Liu Y, Liu Y, et al
    Molecular mechanisms and targeted therapy for the metastasis of prostate cancer to the bones (Review).
    Int J Oncol. 2024;65:104.
    PubMed         Abstract available

  20. IIDA K, Zheng R, Shen R, Nanus DM, et al
    [Corrigendum] Adenoviral neutral endopeptidase gene delivery in combination with paclitaxel for the treatment of prostate cancer.
    Int J Oncol. 2024;65:106.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  21. KENNEDY TAC, Ong WL, Quon H, Cheung P, et al
    Stereotactic radiotherapy for localized prostate cancer: 10-year outcomes from three prospective trials.
    Int J Radiat Oncol Biol Phys. 2024 Sep 16:S0360-3016(24)03368.
    PubMed         Abstract available

  22. UDOVICICH C, Jia AY, Loblaw A, Eapen R, et al
    Evolving Paradigms in Prostate Cancer: The Integral Role of PSMA PET/CT in Primary Staging and Therapeutic Decision-Making.
    Int J Radiat Oncol Biol Phys. 2024 Sep 13:S0360-3016(24)03387.
    PubMed         Abstract available


    J Clin Oncol

  23. MONTORSI F, Longoni M, Briganti A, Gandaglia G, et al
    Improving Assessment of Radiorecurrent Prostate Cancer: Implications for Salvage Reirradiation.
    J Clin Oncol. 2024 Sep 17:JCO2401067. doi: 10.1200/JCO.24.01067.
    PubMed        

  24. SAAD F, Vjaters E, Shore N, Olmos D, et al
    Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.
    J Clin Oncol. 2024 Sep 16:JCO2401798. doi: 10.1200/JCO-24-01798.
    PubMed         Abstract available


    J Nucl Med

  25. GAFITA A, Voter A, Shesadri S, Spitz A, et al
    Initial Experience with [(177)Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction.
    J Nucl Med. 2024 Sep 19:jnumed.124.267723. doi: 10.2967/jnumed.124.267723.
    PubMed         Abstract available


    J Urol

  26. CARLSSON SV, Carroll PR, Hamdy FC
    Reevaluating the Definition of "Clinically Significant" Prostate Cancer as Grade Groups 2-5: An Imperative for Improved Risk Stratification.
    J Urol. 2024 Sep 17:101097JU0000000000004253. doi: 10.1097/JU.0000000000004253.
    PubMed        

  27. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2024 Sep 16:101097JU0000000000004239. doi: 10.1097/JU.0000000000004239.
    PubMed        


    Lancet Oncol

  28. AZAD AA, Bressel M, Tan H, Voskoboynik M, et al
    Sequential [(177)Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study.
    Lancet Oncol. 2024 Sep 13:S1470-2045(24)00440.
    PubMed         Abstract available


    Oncogene

  29. MU Y, Wallenius A, Zang G, Zhu S, et al
    The TbetaRI promotes migration and metastasis through thrombospondin 1 and ITGAV in prostate cancer cells.
    Oncogene. 2024 Sep 20. doi: 10.1038/s41388-024-03165.
    PubMed         Abstract available


    Oncol Rep

  30. ZHOU Y, Ji Z, Yan W, Zhou Z, et al
    [Retracted] Tetramethylpyrazine inhibits prostate cancer progression by downregulation of forkhead box M1.
    Oncol Rep. 2024;52:152.
    PubMed         Abstract available


    Prostate

  31. DE JESUS GNC, Pereira V, Karak P, Shearier E, et al
    A single-center retrospective review of metastatic prostate cancer on PSMA position emission tomography/computed tomography: Beyond lymph nodes and bones.
    Prostate. 2024 Sep 18. doi: 10.1002/pros.24795.
    PubMed         Abstract available

  32. UEKI H, Jimbo N, Terakawa T, Hara T, et al
    Evaluating RB1 and p53 as diagnostic markers in treatment-related neuroendocrine prostate cancer through immunohistochemistry and genomic analysis of RB1 and TP53.
    Prostate. 2024 Sep 15. doi: 10.1002/pros.24791.
    PubMed         Abstract available

  33. KATO T, Sugihara E, Hata Y, Kawakami K, et al
    Diagnostic potential of SDHB mRNA contained in serum extracellular vesicles among patients with prostate cancer.
    Prostate. 2024 Sep 15. doi: 10.1002/pros.24792.
    PubMed         Abstract available

  34. TANAKA N, Izumi K, Nakai Y, Shima T, et al
    Dose modification in enzalutamide and abiraterone plus prednisolone for castration-resistant prostate cancer: A subanalysis from the ENABLE study for PCa.
    Prostate. 2024 Sep 20. doi: 10.1002/pros.24796.
    PubMed         Abstract available


    Radiol Imaging Cancer

  35. RAJEEV R, Hussain HK
    Artificial Intelligence versus Radiologists: A Comparative Analysis for Detecting Clinically Significant Prostate Cancer.
    Radiol Imaging Cancer. 2024;6:e249020.
    PubMed        

  36. GURBANI S, Mao H
    A Novel PET Radiotracer for Detection of Neuroendocrine Tumors of the Lung and Prostate.
    Radiol Imaging Cancer. 2024;6:e249019.
    PubMed        


    Urology

  37. DALL CP
    Editorial comment on "Stereotactic Body Radiation Adoption Impacts Prostate Cancer Treatment Patterns".
    Urology. 2024 Sep 16:S0090-4295(24)00814-8. doi: 10.1016/j.urology.2024.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.